3 results
With the goal of improving kidney function and without causing an increased number of rejections, is it possible to reduce tacrolimus dosage through the use of the previously-mentioned immunosupressives after month three.
Primary:To investigate the safety and tolerability of 60 mg 3 times daily doses of GSK2982772 in subjects with moderate to severe ulcerative colitis.Secondary:To assess the preliminary efficacy, biomarkers, histological disease activity, response…
The aim of this study is to compare the effectiveness of TAC with MMF as a second line treatment for AIH. Proportion of patients with CR after 12 months of treatment will be the primary outcome parameter to determine effectivity.